KSR VS TELEFLEX AND PFIZER VS APOTEX: IMPLICATIONS FOR NOVARTIS LITIGATION IN INDIA
Its been a while since the Court of Appeals for the Federal Circuit invalidated Pfizer’s patents covering Norvarsc, one of their best selling drugs used by high blood pressure patients. Close on the heels of this important judgment that in some ways endorses a section 3(d) kind of approach (an issue pertinent to the ongoing Novartis litigation), comes another judgment, KSR vs Teleflex, where the United States Supreme Court raises the bar for “non obviousness”.As some of you may know, […]
KSR VS TELEFLEX AND PFIZER VS APOTEX: IMPLICATIONS FOR NOVARTIS LITIGATION IN INDIA Read More »





